Therapeutic effects of Serelaxin in acute heart failure
Over the past few decades, research on the peptide hormone, relaxin, has significantly improved our understanding of its biological actions under physiological and diseased conditions. This has facilitated the conducting of clinical trials to explore the use of serelaxin (human recombinant relaxin)....
| Main Authors: | , , , |
|---|---|
| Format: | Journal article |
| Published: |
Japanese Circulation Society
2014
|
| _version_ | 1797083405477740544 |
|---|---|
| author | Du, X Hewitson, T Nguyen, M Samuel, C |
| author_facet | Du, X Hewitson, T Nguyen, M Samuel, C |
| author_sort | Du, X |
| collection | OXFORD |
| description | Over the past few decades, research on the peptide hormone, relaxin, has significantly improved our understanding of its biological actions under physiological and diseased conditions. This has facilitated the conducting of clinical trials to explore the use of serelaxin (human recombinant relaxin). Acute heart failure (AHF) is a very difficult to treat clinical entity, with limited success so far in developing new drugs to combat it. A recent phase-III RELAX-AHF trial using serelaxin therapy given during hospitalization revealed acute (ameliorated dyspnea) and chronic (improved 180-day survival) effects. Although these findings support a substantial improvement by serelaxin therapy over currently available therapies for AHF, they also raise key questions and stimulate new hypotheses. To facilitate the development of serelaxin as a new drug for heart disease, joint efforts of clinicians, research scientists and pharmacological industries are necessary to study these questions and hypotheses. In this review, after providing a brief summary of clinical findings and the pathophysiology of AHF, we present a working hypothesis of the mechanisms responsible for the observed efficacy of serelaxin in AHF patients. The existing clinical and preclinical data supporting our hypotheses are summarized and discussed. The development of serelaxin as a drug provides an excellent example of the bilateral nature of translational research |
| first_indexed | 2024-03-07T01:41:20Z |
| format | Journal article |
| id | oxford-uuid:96f2a3bf-0012-44df-b9b4-06ae5e3f3229 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T01:41:20Z |
| publishDate | 2014 |
| publisher | Japanese Circulation Society |
| record_format | dspace |
| spelling | oxford-uuid:96f2a3bf-0012-44df-b9b4-06ae5e3f32292022-03-26T23:56:21ZTherapeutic effects of Serelaxin in acute heart failureJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:96f2a3bf-0012-44df-b9b4-06ae5e3f3229Symplectic Elements at OxfordJapanese Circulation Society2014Du, XHewitson, TNguyen, MSamuel, COver the past few decades, research on the peptide hormone, relaxin, has significantly improved our understanding of its biological actions under physiological and diseased conditions. This has facilitated the conducting of clinical trials to explore the use of serelaxin (human recombinant relaxin). Acute heart failure (AHF) is a very difficult to treat clinical entity, with limited success so far in developing new drugs to combat it. A recent phase-III RELAX-AHF trial using serelaxin therapy given during hospitalization revealed acute (ameliorated dyspnea) and chronic (improved 180-day survival) effects. Although these findings support a substantial improvement by serelaxin therapy over currently available therapies for AHF, they also raise key questions and stimulate new hypotheses. To facilitate the development of serelaxin as a new drug for heart disease, joint efforts of clinicians, research scientists and pharmacological industries are necessary to study these questions and hypotheses. In this review, after providing a brief summary of clinical findings and the pathophysiology of AHF, we present a working hypothesis of the mechanisms responsible for the observed efficacy of serelaxin in AHF patients. The existing clinical and preclinical data supporting our hypotheses are summarized and discussed. The development of serelaxin as a drug provides an excellent example of the bilateral nature of translational research |
| spellingShingle | Du, X Hewitson, T Nguyen, M Samuel, C Therapeutic effects of Serelaxin in acute heart failure |
| title | Therapeutic effects of Serelaxin in acute heart failure |
| title_full | Therapeutic effects of Serelaxin in acute heart failure |
| title_fullStr | Therapeutic effects of Serelaxin in acute heart failure |
| title_full_unstemmed | Therapeutic effects of Serelaxin in acute heart failure |
| title_short | Therapeutic effects of Serelaxin in acute heart failure |
| title_sort | therapeutic effects of serelaxin in acute heart failure |
| work_keys_str_mv | AT dux therapeuticeffectsofserelaxininacuteheartfailure AT hewitsont therapeuticeffectsofserelaxininacuteheartfailure AT nguyenm therapeuticeffectsofserelaxininacuteheartfailure AT samuelc therapeuticeffectsofserelaxininacuteheartfailure |